FY2026 EPS Estimates for MetaVia Decreased by Zacks Research

MetaVia Inc. (NASDAQ:MTVA) – Analysts at Zacks Research decreased their FY2026 earnings per share (EPS) estimates for MetaVia in a research note issued on Wednesday, August 12th. Zacks Research analyst D. Bautz now forecasts that the company will earn ($1.97) per share for the year, down from their prior estimate of ($1.87). The consensus estimate for MetaVia’s current full-year earnings is ($2.79) per share.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08).

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating on shares of MetaVia in a report on Friday, July 10th. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, MetaVia has an average rating of “Hold” and a consensus price target of $20.00.

MetaVia Price Performance

Shares of MTVA stock opened at $1.48 on Monday. The stock’s fifty day moving average price is $1.59 and its 200 day moving average price is $1.68. MetaVia has a 1-year low of $0.97 and a 1-year high of $19.03. The company has a market cap of $7.64 million, a price-to-earnings ratio of -0.46 and a beta of 0.95.

Institutional Trading of MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC acquired a new stake in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. Institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.